Nomizo T, Yamamoto H, Murayama T, Fukata H, Nakamura Y, Sonomura M, Okuno A, Kanda N, Watanabe C, Kita H. Immune-related adverse events caused by combined immune checkpoint inhibitor therapy with nivolumab and ipilimumab for lung cancer. Trends Immunother. [Internet]. 2022 Jan. 14 [cited 2025 Apr. 3];6(1). Available from: https://ojs.ukscip.com/index.php/ti/article/view/425